Information Library
Business transformation - Managed Partnerships
To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.
- Sort by: Most Recent
- Title
-
CRO Partnerships 2010
April 12 - April 14, 2010
19th Annual Partnerships with CROs conference -
Should Venture Firms Bundle Their Biotech Portfolios?
June 29, 2009
Ron Wooten, president of NovaQuest, an investment and business-development unit of Quintiles Transnational Corp., a contract-research organization, thinks so. -
Anatomy of a Managed Partnership
May 26, 2009
Partnering affords pharma the opportunity to bolster development pipelines without taking on additional risk or adding to fixed costs. -
Making the Most of a Smart Move
March 26, 2009
In late 2007, Scotland-based ProStrakan Group plc seemed to have everything going for it: four new European product introductions planned for an 18-month period and near-term product launches with an aggregate peak sales potential of $400 to $500 million, both backed by a 340-person pan-European salesforce. -
Grabbing a Leadership Position
March 26, 2009
Astellas-NovaQuest Alliance Establishes Market Leadership Platform for Vesicare -
Driving Near Term Sales & Savings
March 26, 2009
NovaQuest’s predecessor, PharmaBio Development, funded a dedicated sales force of 150 experienced Innovex cardiovascular representatives for two years, in return for a five-year royalty on the net sales of Advicor and its predecessor product, Niaspan®. PharmaBio also received warrants to purchase shares of Kos Pharmaceuticals stock. -
Gain Capital & Retain Value
March 24, 2009
Cell Therapeutics was in need of capital to fund ongoing development expenses, but was not interested in further equity dilution. As an alternative, they considered monetizing a royalty interest in Trisenox®, their only marketed oncology product. -
Out with the Old
August 1, 2008
Ron Wooten SAP Conference Video 5 -
Massive Change Ahead
August 1, 2008
Ron Wooten SAP Conference Video 3 -
Technology Drives Value
August 1, 2008
Ron Wooten SAP Conference Video 2